Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals

Diabetologia

Volumn 53, Issue 8, 2010, Pages 1568-1575

  Zanchi, A ^a   Maillard, M ^a   Jornayvaz, F R ^b   Vinciguerra, M ^c   Deleaval, P ^a   Nussberger, J ^a   Burnier, M ^a   Pechere Bertschi, A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Clearance; Glitazones; Hormones; Hypertension; Kidney; Sodium; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDOSTERONE; ASPARTATE AMINOTRANSFERASE; BRAIN NATRIURETIC PEPTIDE; CREATININE; METFORMIN; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; SODIUM INTAKE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; HIGH SODIUM INTAKE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM ABSORPTION; SODIUM INTAKE; SODIUM RESTRICTION; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; ANALYSIS OF VARIANCE; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM;

ANALYSIS OF VARIANCE; BLOOD PRESSURE; BODY WEIGHT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; NATRIURETIC PEPTIDE, BRAIN; SODIUM, DIETARY; THIAZOLIDINEDIONES;

EID: 77955515855     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1756-2     Document Type: Article

References (27)

1. SE Kahn SM Haffner MA Heise, et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 10.1056/NEJMoa066224 1:CAS:528:DC%2BD28Xht12ntrzF 17145742 (Pubitemid 44903747)
2. RM Lago PP Singh RW Nesto 2007 Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials Lancet 370 1129 1136 10.1016/S0140-6736(07)61514-1 1:CAS:528:DC%2BD2sXhtFSntLzO 17905165 (Pubitemid 47464583)
3. E Erdmann RG Wilcox 2008 Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure Eur Heart J 29 12 20 10.1093/eurheartj/ehm529 1:CAS:528:DC%2BD1cXis1Sqtr4%3D 18167366
4. HJ Dargie PR Hildebrandt GA Riegger, et al. 2007 A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure J Am Coll Cardiol 49 1696 1704 10.1016/j.jacc.2006.10.077 1:CAS:528:DC%2BD2sXksFWqtLc%3D 17448371 (Pubitemid 46589926)
5. A Zanchi A Chiolero M Maillard J Nussberger HR Brunner M Burnier 2004 Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men J Clin Endocrinol Metab 89 1140 1145 10.1210/jc.2003-031526 1:CAS:528: DC%2BD2cXisVWrtbk%3D 15001599 (Pubitemid 38368402)
6. Y Guan C Hao DR Cha, et al. 2005 Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption Nat Med 11 861 866 10.1038/nm1278 1:CAS:528:DC%2BD2MXmvFemsLY%3D 16007095 (Pubitemid 41161118)
7. H Zhang A Zhang DE Kohan RD Nelson FJ Gonzalez T Yang 2005 Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention Proc Natl Acad Sci USA 102 9406 9411 10.1073/pnas.0501744102 1:CAS:528:DC%2BD2MXlvF2rsb4%3D 15956187 (Pubitemid 40923576)
8. J Karalliedde R Buckingham M Starkie D Lorand M Stewart G Viberti 2006 Effect of various diuretic treatments on rosiglitazone-induced fluid retention J Am Soc Nephrol 17 3482 3490 10.1681/ASN.2006060606 1:CAS:528:DC%2BD28XhtlGiu7bL 17093067 (Pubitemid 44865290)
9. T Yang S Soodvilai 2008 Renal and vascular mechanisms of thiazolidinedione-induced fluid retention PPAR Res 2008 943614 18784848
10. S Saad DJ Agapiou XM Chen V Stevens CA Pollock 2009 The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells Nephrol Dial Transplant 24 1130 1141 10.1093/ndt/gfn614 1:CAS:528:DC%2BD1MXjsFeksLc%3D 18997160
11. P Gosse P Ansoborlo VV Jullien P Lemetayer J Clementy 1997 Ambulatory blood pressure and left ventricular hypertrophy Blood Press Monit 2 70 74 10234095
12. M Burnier B Rutschmann J Nussberger, et al. 1993 Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects Hypertension 22 339 347 1:CAS:528:DyaK3sXms1aitbk%3D 8349327
13. K Mather A Hunt H Steinberg, et al. 2001 Repeatability characteristics of simple indices of insulin resistance: implications for research applications J Clin Endocrinol Metab 86 5457 5464 10.1210/jc.86.11.5457 1:CAS:528: DC%2BD3MXos1Kqt7s%3D 11701722 (Pubitemid 33070275)
14. JL Magnin LA Decosterd C Centeno M Burnier J Diezi J Biollaz 1996 Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: variability of urine matrices circumvented by cation exchange solid phase extraction Pharm Acta Helv 71 237 246 10.1016/S0031-6865(96)00020-9 1:CAS:528:DyaK28XmvFClur4%3D 8921742 (Pubitemid 26358936)
15. J Nussberger T Fasanella d'Amore M Porchet, et al. 1987 Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers J Cardiovasc Pharmacol 9 39 44 1:CAS:528:DyaL2sXpsFyntg%3D%3D 2434792 (Pubitemid 17212750)
16. K Poulsen J Jorgensen 1974 An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody J Clin Endocrinol Metab 39 816 825 10.1210/jcem-39-5-816 1:CAS:528:DyaE2MXltlWhtw%3D%3D 4370699
17. J Nussberger B Waeber HR Brunner JF Burris W Vetter 1984 Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods J Lab Clin Med 104 789 796 1:CAS:528:DyaL2cXmt1artrY%3D 6491472
18. J Nussberger V Mooser G Maridor L Juillerat B Waeber H Brunner 1990 Caffeine-induced diuresis and atrial natriuretic peptides J Cardiovasc Pharmacol 15 685 691 10.1097/00005344-199005000-00001 1:CAS:528:DyaK3cXktVSms7s%3D 1692926
19. Y Miyazaki A Mahankali M Matsuda, et al. 2002 Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 87 2784 2791 10.1210/jc.87.6.2784 1:CAS:528: DC%2BD38XkvFaku74%3D 12050251 (Pubitemid 34655345)
20. SK Kim KY Hur HJ Kim, et al. 2007 The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment Eur J Endocrinol 157 167 174 10.1530/EJE-07-0043 1:CAS:528:DC%2BD2sXps1Kjt7s%3D 17656594 (Pubitemid 47233120)
21. YC Hwang EY Lee WJ Lee, et al. 2008 Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients Metabolism 57 479 487 10.1016/j.metabol.2007.11.008 1:CAS:528: DC%2BD1cXjtVensrc%3D 18328348 (Pubitemid 351317961)
22. SR Smith L de Jonge J Volaufova Y Li H Xie GA Bray 2005 Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial Metabolism 54 24 32 10.1016/j.metabol.2004.07.008 1:CAS:528: DC%2BD2cXhtVansb3E 15562376 (Pubitemid 39572453)
23. A Basu MD Jensen F McCann D Mukhopadhyay MJ Joyner RA Rizza 2006 Effects of pioglitazone vs glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes Diabetes Care 29 510 514 10.2337/diacare.29.03. 06.dc05-2004 1:CAS:528:DC%2BD28XislOksLk%3D 16505497
24. V Vallon E Hummler T Rieg, et al. 2009 Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity J Am Soc Nephrol 20 721 729 10.1681/ASN.2008040415 1:CAS:528:DC%2BD1MXltFOqurc%3D 19158355
25. S Tiwari ER Blasi JR Heyen AD McHarg CM Ecelbarger 2008 Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats Pharmacol Res 57 383 392 10.1016/j.phrs.2008.03.013 1:CAS:528:DC%2BD1cXmvFSiu70%3D 18468451
26. A Zanchi C Perregaux M Maillard D Cefai J Nussberger M Burnier 2006 The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats Am J Physiol Endocrinol Metab 291 E1228 E1234 10.1152/ajpendo.00171.2006 1:CAS:528:DC%2BD2sXjvFSg 16835400 (Pubitemid 44911032)
27. PA Sarafidis PM Nilsson 2006 The effects of thiazolidinediones on blood pressure levels-a systematic review Blood Press 15 135 150 10.1080/ 08037050600853720 1:CAS:528:DC%2BD28Xpt1ylsLk%3D 16864155 (Pubitemid 44644465)